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Abstract
Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved 
for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to 
provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic 
medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 
per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed 
at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the 
prescribing of such medications is increasing.
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Autism spectrum disorder (ASD) is a persistent neurodevel-
opmental condition characterised by social communication 
impairment and stereotyped, repetitive patterns of behaviour 
(APA 2013). A previous study in the United Kingdom (UK) 
using electronic primary care data showed that the incidence 
rate of pervasive developmental disorders (PDDs) increased 
from 0.40/10,000 (95% CI 0.30–0.54) to 2.98/10,000 (95% 
CI 2.56–3.47) person-years between 1991 and 2001 (Smeeth 
et al. 2004b). Another study showed that 70% of 112 chil-
dren with autism had at least one neuropsychiatric comorbid 
disorder, of which the most common diagnosis was social 
anxiety disorder (29.2%; 95% CI 13.2–45.1) (Simonoff et al. 
2008).
Psychotropic medications, such as antipsychotics, anti-
depressants, antiepileptic drugs and stimulants, have been 
used for ASD patients with associated comorbid conditions 
(National Collaborating Centre for Mental Health 2012). 
There is, however, limited evidence to guide psychotropic 
medication prescribing in the ASD population. Risperi-
done is the only drug approved by the European Medicines 
Agency (EMA), the Medicines and Healthcare Products 
Regulatory Agency (MHRA) of the UK, and the Australian 
Therapeutic Goods Administration (TGA) for the manage-
ment of behavioural disturbance in children and adolescents 
with autism and conduct disorder (European Medicines 
Agency 2007; World Health Organisation 2013).
ASD can lead to impairment of the quality of life and the 
productivity of affected persons and their families; therefore, 
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ASD and its complications have a significant impact on soci-
ety and the individual, which should not be ignored. The aim 
of this study was to provide up-to-date information on the 
prevalence of ASD, psychiatric comorbidities and psycho-
tropic medication prescribing in a UK population sample 
with individuals from all ages. We also aimed to examine 
the average duration of psychotropic treatment in treated 
patients.
Methods
Study Design
This is an observational descriptive study conducted to 
investigate the incidence and prevalence of ASD.
Data Source
We used data from The Health Improvement Network 
(THIN) for this study. THIN is a primary care database of 
anonymised general practice records, covering a period from 
the early 1990s to the present day, of more than 11 million 
individuals, including 3.7 million active patients, which cov-
ers approximately 6% of the UK population (Fardet et al. 
2017; Blak et al. 2011). THIN database is representative 
of the UK population (Blak et al. 2011), and it has been 
validated for use as a source of data for pharmacoepidemio-
logical research (Lewis et al. 2007). Only individuals with a 
record that passed the validation check were included in the 
study (IMS Health 2015).
Ethical Approval
Ethical approval for this fully anonymised study was 
obtained from the Scientific Review Committee (SRC) 
which was established to review research using the THIN 
database (Ref: 18THIN010).
Study Population
All individuals in the THIN database from all age groups 
who had a diagnosis record of ASD in the study period 
between 1st of January 2009 and 31st of December 2016 
were identified.
For each patient, the latest of either the date of the 
patient’s registration at the general practice or the date that 
the general practice began using a computerised clinical 
management system was identified as the patient’s start date. 
Only patients who had an observation period of at least 12 
months available from their start date were included. The 
date of the first recorded diagnosis of ASD following the 
patient’s start date was identified as the patient’s index date. 
Age at first recorded diagnosis was defined as the time 
between the birth year and the year of the diagnosis. Figure 1 
illustrates the study population.
Incident Cases Definition
For each patient, the records were screened from the start 
date to identify the incident cases throughout the study 
period (2009–2016). ASD-incident patients were defined 
as (1) those who had a first diagnosis of ASD following the 
1st-year screening period and (2) those with an ASD diag-
nosis aged < 2 years during the 12-month screening period 
(ASD is usually diagnosed at age two or older; if the patient 
had a record under 2 years of age, they were counted as an 
incident case).
Fombonne et al. have validated the ASD Read codes list 
(2004); this code list has been used in other published stud-
ies carried out on UK primary care databases (Smeeth et al. 
2004a, b).
Additionally, we set out to ascertain medications pre-
scribed to people with ASD and neuropsychiatric comor-
bidities by using related treatment/diagnostic Read codes.
Neuropsychiatric Comorbidities
Based on the NICE guideline on the management of ASD 
in individuals under 19 years of age (National Institute for 
Health and Care Excellence 2013) and a literature review 
(Simonoff et al. 2008; Murray et al. 2014), the neuropsy-
chiatric comorbidities of interest selected were: attention 
deficit hyperactivity disorder (ADHD), anxiety, behavioural/
conduct disorders, intellectual disabilities, sleep disorders, 
depression, epilepsy, schizophrenia and tic disorders. Read 
codes for neuropsychiatric comorbidities were obtained 
from the official website of the University of Cambridge 
Fig. 1  Study population. aVision software is a computerised clinical 
management system used by general practices to record patient infor-
mation. bStart date is the latest of either the date of the patient’s reg-
istration at the general practice or the date that the general practice 
began using vision software. R Date date of patient’s registration in 
the GP, ASD Dx autism spectrum disorder diagnosis, Psych Rx psy-
chotropic drug prescription, NC Dx neuropsychiatric comorbidity 
diagnosis
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(University of Cambridge) and published studies (Barnett 
et al. 2012; Murray et al. 2014; Hire 2016; Carey et al. 
2017), and the descriptions of the codes have been reviewed 
by a psychiatrist in our research team.
Psychotropic Medication
The prescriptions of the study drugs for each patient 
recorded on or after their index date were identified in THIN, 
and the annual proportions of the ASD cohort prescribed 
psychotropic medications were calculated for each psy-
chotropic drug class. Drug codes were used to identify the 
records of psychotropic medications in the British National 
Formulary (BNF) (British Medical Association 2009), 
which include the following drug classes: antipsychotic, 
antidepressant, antiepileptic, anxiolytic, stimulant and 
hypnotic. Drugs included in this study are listed in Online 
Appendix A.
Analysis
The annual incidence of ASD per 100 persons was calcu-
lated by dividing the number of incident cases in each year 
by the total number of the THIN mid-year population (MYP) 
of the same year multiplied by 100.
Prevalent cases of ASD were defined as all patients hav-
ing an ASD diagnosis. Similar to the annual incidence, the 
annual prevalence of ASD per 100 was calculated by divid-
ing the number of prevalent cases in each year by the total 
number of the THIN MYP of the same year multiplied by 
100.
Both annual incidence and prevalence were strati-
fied by gender and age groups: children at age 2 years or 
younger, 3–5-year-olds (young children), 6–12-year-olds 
(children), 13–17-year-olds (adolescents), 18–24-year-olds 
(young adults), 25–64-year-olds (adults) and ≥ 65-year-olds 
(elderly). It should be noted that operational definitions have 
been used for both incidence and prevalence; the true figures 
would be dependent on complete, accurate diagnosis—see 
discussion.
The annual proportion of ASD patients treated with psy-
chotropic drugs was calculated by dividing the number of 
treated patients in each class in a year by the ASD preva-
lent cases in the same year multiplied by 100. A secondary 
analysis was performed by excluding patients with only one 
psychotropic drug prescription.
The Kaplan–Meier survival analysis was used to estimate 
the average discontinuation rate of psychotropic drugs in 
this cohort. The percentage of the ASD cohort having other 
neuropsychiatric diagnoses was calculated by dividing the 
number of patients having a record of each diagnosis over 
the total ASD cohort multiplied by 100. Analyses were 
performed using the Statistical Analysis System (SAS) ver-
sion 9.4.
Results
Characteristics of the ASD Cohort
Over the study period, there were 20,194 patients with at 
least one recorded diagnosis of ASD, 78% of them were 
male. The mean age of the first recorded diagnosis among 
females was 14.03 (SD 11.9) years and 11.5 (SD 10.7) years 
among males. Further details of the study cohort are pro-
vided in Table 1.
Prevalence/Incidence of ASD Diagnoses
Over the study period, the prevalence of ASD increased 3.3-
fold from 0.1095 per 100 persons (95% CI 0.1094–0.1096) 
in 2009 to 0.3555 per 100 persons (95% CI 0.3553–0.3557) 
in 2016. Generally, the prevalence of ASD was higher 
among males than females. In 2016, the ASD prevalence 
was 0.1576 per 100 persons (95% CI 0.1574–0.1577) and 
0.5576 per 100 persons (95% CI 0.5573–0.5580) in females 
and males, respectively. The prevalence of ASD was highest 
in individuals in the age groups of 6–12 years (children) and 
13–18 years (adolescents). In 2016, the prevalence of ASD 
was 1.6092 (95% CI 1.6077–1.6107) per 100 persons in chil-
dren and 1.5694 per 100 persons (95% CI 1.5678–1.5710) in 
adolescents. Figure 2a, b shows the detailed annual preva-
lence of ASD.
The incidence of ASD rose 2.9-fold during the period 
2009–2016: 0.0226 per 100 persons (95% CI 0.0226–0.0227) 
to 0.0647 per 100 persons (95% CI 0.0646–0.0648). The 
incidence rate increased 5.1-fold among females and 2.5-fold 
among males. During the study period, the incidence of ASD 
was the highest in 2016 among young children aged from 
3 to 5, at 0.4505 per 100 persons (95% CI 0.4493–0.4517). 
The annual ASD incidence is shown in Fig. 3a, b.
Drug Prescribing
Within the total cohort, 6529 patients (33.4%) received at 
least one psychotropic prescription; overall, 270,391 psycho-
tropic prescriptions were issued. The prescribing rate was 
significantly greater among females (37.2% of the female 
cohort) compared to males (31.0% of the male cohort), 
p < 0.0001. Among the males, the three most commonly 
prescribed psychotropic drugs were hypnotics (in 30.5% 
of treated males), antidepressants (24.6%) and stimulants 
(20.5%). Whereas in the females, the three most commonly 
prescribed psychotropic drugs were antidepressants (38.8%), 
hypnotics (24.1%) and antipsychotics (12.5%).
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The highest numbers of prescriptions issued throughout the 
study period were for methylphenidate (46,393 prescriptions 
were identified, which comprised 17.1% of all psychotropic 
drug prescriptions), followed by melatonin (38,520 prescrip-
tions, 14.2%) and risperidone (19,800 prescriptions, 7.3%). 
Valproic acid was the most frequently prescribed antiepileptic 
drug (17,271 prescriptions, 6.3%). The most commonly pre-
scribed antidepressants were fluoxetine (15,252 prescriptions, 
5.6%) and sertraline (14,997 prescriptions, 5.5%).
The percentage of patients prescribed both antidepressant 
and hypnotic drugs approximately doubled over the period 
from 2009 to 2016: from 6.2% (95% CI 5.6–6.8) to 11.5% 
(95% CI 10.9–12.1) and from 5.5% (95% CI 5.0–6.2) to 
11.2% (95% CI 10.6–11.8), respectively. For the remaining 
psychotropic drug classes, the percentage of patients pre-
scribed these medications remained relatively steady over 
the study period. A secondary analysis conducted by exclud-
ing patients with only one prescription for each drug class 
resulted in similar findings to those of the primary analysis. 
Figure 4 shows the annual percentage of those prescribed 
psychotropic drugs in the total ASD cohort.
Kaplan–Meier survival curves demonstrated that approxi-
mately one-third of those prescribed antipsychotic drugs, 
403 patients of 1254 (32.1%), were on continuous antipsy-
chotic therapy for more than 1 year, and 6.1% (77 patients) 
continued for up to 5 years. Furthermore, 29.9% (190 of 
634) remained on risperidone therapy for more than 1 year, 
and 31.5% of those prescribed aripiprazole remained on the 
treatment for more than 1 year. For antidepressants, almost 
a quarter of the patients (25.8%; 650 of 2516 patients) con-
tinued on therapy for more than a year, while 2.9% of them 
remained on antidepressants for more than 5 years. 25% of 
patients prescribed fluoxetine remained on the treatment for 
more than 1 year. More than half of the patients prescribed 
antiepileptics continued on therapy for 1 year, and 12.5% of 
them continued for more than 5 years. The majority of ASD 
patients prescribed anxiolytic medication (94%) had stopped 
the treatment after 1 year. For patients treated with hypnotics 
and stimulants, 21.5% and 32% continued treatment for up to 
1 year, respectively. The detailed survival analysis for psy-
chotropic drugs identified in this study is illustrated in Fig. 5.
Table 1  Cohort characteristics Cohort characteristics All Male Female
Number of subjects (%) with at least one 
diagnosis of ASD
20194 (100%) 15923 (78.9%) 4271 (21.1%)
Age at first recorded diagnosis of ASD (%)
 0–2 369 (1.8%) 307 (1.5%) 62 (0.3%)
 3–5 5094 (25.2%) 4225 (20.9%) 869 (4.3%)
 6–12 8601 (42.5%) 7021 (34.7%) 1580 (7.8%)
 13–18 3263 (16.1%) 2325 (11.5%) 938 (4.6%)
 19–24 858 (4.2%) 609 (3.0%) 249 (1.2%)
 25–64 1944 (9.6%) 1389 (6.8%) 555 (2.7%)
  ≥ 65 65 (0.3%) 47 (0.2%) 18 (0.09%)
Neuropsychiatric comorbidities (%)
 Attention deficit hyperactivity disorder 
(ADHD)
2897 (14.3) 2454 (12.1) 443 (2.2)
 Anxiety 3077 (15.2) 2085 (10.3) 992 (4.9)
 Behavioural/conduct disorders 6208 (30.7) 5023 (24.9) 1185 (5.8)
 Intellectual disabilities 2093 (10.3) 1591 (7.8) 502 (2.5)
 Sleep disorders 879 (4.3) 682 (3.4) 197 (0.9)
 Depression 2234 (11.0) 1459 (7.2) 775 (3.8)
 Epilepsy 909 (4.5) 652 (3.2) 257 (1.3)
 Schizophrenia 152 (0.7) 117 (0.5) 35 (0.2)
 Tic disorders 411 (2.0) 359 (1.8) 52 (0.2)
Psychotropic medication prescribing (%)
 Antidepressant 1836 (9.0) 1218 (6.0) 618 (3.0)
 Antiepileptic 585 (2.8) 418 (2.0) 167 (0.8)
 Antipsychotic 814 (4.0) 614 (3.0) 200 (1.0)
 Anxiolytic 237 (1.1) 162 (0.8) 75 (0.3)
 Hypnotic 1894 (9.3) 1510 (7.4) 384 (1.9)
 Stimulant 1163 (5.7) 1015 (5.0) 148 (0.7)
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Neuropsychiatric Comorbidities
Of the total ASD cohort, 57.3% of the patients had at least 
one neuropsychiatric comorbidity. The most commonly 
prescribed psychotropic drug classes in these patients were 
antidepressants (14.3%) and hypnotics (10.5%). The three 
most common neuropsychiatric diagnoses accompanying 
ASD were behavioural/conduct disorders at 30.7% (95% CI 
30.1–31.3), anxiety at 15.2% (95% CI 14.7–15.7) and ADHD 
at 14.3% (95% CI 13.8–14.8). The percentage of diagno-
ses was higher in males than females for ADHD (15.4% 
and 10.3%) and behavioural/conduct disorders (31.5% and 
27.7%). However, the proportion of patients with anxiety 
was greater among females, at 23.2% compared to 13.1% in 
males. Almost twice as many females (18.1%) than males 
(9.1%) were diagnosed with depression. For the remaining 
neuropsychiatric diagnoses, the proportions were similar for 
both males and females. Table 1 provides a full description 
of the numbers of neuropsychiatric diagnoses.
Among ASD patients on antipsychotics, more than half 
(53.3%) were diagnosed with behavioural/conduct disorders 
and 34.9% as having anxiety, whereas 8.1% were diagnosed 
with no additional neuropsychiatric comorbidities identified. 
Among the patients with ASD but no comorbid neuropsychi-
atric diagnoses, 87.6% of them were not on any psychotropic 
therapy; of the remaining 12.4%, 7.7% were prescribed hyp-
notics and 2% were on antidepressants. In those who had neu-
ropsychiatric comorbidities, 52.8% were not on psychotropic 
therapy, although almost 60% of these patients had behav-
ioural/conduct disorders.
Fig. 2  a ASD annual preva-
lence. b ASD annual prevalence 
stratified by age groups
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Discussion
Main Findings
This study has extended the previous findings of research 
in this area by (1) providing the most recent and com-
prehensive description of ASD in the UK, (2) analys-
ing a broader cohort, including patients with ASD of all 
age groups, and (3) using survival analysis to examine 
the duration of treatment for different psychotropic drug 
classes over the study period.
The incidence and prevalence of ASD have increased 
markedly over recent years. This probably reflects the cur-
rent broader diagnostic criteria for ASD and increasing 
awareness of the condition. In our study, the incidence 
and prevalence of ASD increased 2.9-fold and 3.3-fold, 
respectively, from 2009 to 2016. During the study period, 
the greatest prevalence of ASD was seen in children 
(6–12-year-olds), followed by adolescents (13–18-year-
olds) and then young children (3–5-year-olds). Similar 
trends were observed in the study by Murray et al. which 
covered the period from 1992 to 2008 (2014). However, 
Fig. 3  a ASD annual incidence. 
b ASD annual incidence strati-
fied by age groups
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the increase in the incidence and prevalence of ASD from 
1992 to 2008 were much higher in Murray’s study (23.7- 
and 64.6-fold) compared to our findings. This could be 
because, by 2009, when our study period started, the 
broader diagnostic criteria of ASD were already well 
established and the level of parental and societal aware-
ness of the condition had increased. In the US, the preva-
lence of ASD in 2014 in children aged 8 years was 1.68 
per 100 children. This was comparable to our findings in 
2014: the prevalence was 1.1870 per 100 in children aged 
6–12 (95% CI 1.1859–1.1881). A 3.7:1 male-to-female 
ratio of ASD prevalence was identified in our study. This is 
similar to what was found in a prevalence study conducted 
in Canada over the period 2004–2015 (Hamad et al. 2019).
Although in our study there were no restrictions on age, 
the findings regarding psychotropic drug prescribing were 
consistent with the findings of Murray et al. (2014), in 
which, of the total cohort, 28.7% were on psychotropic 
therapy, compared with 32.3% in our study. In both studies 
the prescribing rate was higher among females than males. 
Furthermore, over the two study periods, from 1992 to 
2008 and from 2009 to 2016, the three most commonly 
prescribed drugs remained the same: methylphenidate, 
risperidone and melatonin. This prescribing pattern cor-
responds with the most common comorbid neuropsychi-
atric diagnoses which were recognised: 14.3% of the total 
cohort were found to have a record of an ADHD diagnosis 
and 30.7% had a record of behavioural disorders. Never-
theless, the percentage of patients recorded as having a 
sleep disorder (4.3%) was less than what was expected 
based on the high rate of hypnotic drug prescribing (24.1% 
of treated females and 30.5% of treated males), which may 
be due to the under-recording of sleep disorder diagnoses. 
In studies that have specifically examined sleep disorders 
in children with ASD, the rate is usually very high com-
pared to typically developing children, ranging from 40 to 
80% (Devnani and Hegde 2015). In our study, some of the 
patients may have unrecorded comorbidities or comorbidi-
ties that were not identified (per protocol) in this cohort.
Aripiprazole and risperidone are antipsychotic drugs 
shown to be effective in the management of behavioural 
symptoms in children and adolescents with ASD (Owen 
et al. 2009; Shea et al. 2004). In two multinational studies 
investigating the treatment pattern of ASD, risperidone 
Fig. 4  Annual percentage of psychotropic drug users per ASD cohort
Fig. 5  Survival analysis curves 
for psychotropic drug
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was the most commonly prescribed drug in most of the 
countries involved (Hsia et al. 2014; Wong et al. 2014). 
The rate of psychotropic drug prescribing was higher in 
the US compared to the UK (approximately two-thirds of 
the total ASD cohort had at least one psychotropic drug 
prescription compared to one-third of our cohort) (Spencer 
et al. 2013; Houghton et al. 2017). In the US, both risperi-
done and aripiprazole are approved for the management of 
behavioural disorders accompanying autism in children, 
while in the UK, risperidone is the only antipsychotic 
drug which has been approved for the same indication. 
Although aripiprazole has not yet been approved in the UK 
for the treatment of ASD, in our cohort almost 2% of psy-
chotropic medication prescriptions were for aripiprazole 
(5241 aripiprazole prescriptions were issued). Moreover, 
31.5% of patients treated with aripiprazole remained on 
the drug for more than 1 year. A study conducted in a 
secondary care setting in the UK found that over a 6-year 
observation period, 10% of 3482 children with ASD 
and aged below 18 were on antipsychotic therapy: 55% 
(n = 191) on risperidone and 32% (n = 112) on aripiprazole 
(Downs et al. 2016).
Nearly half of the ASD patients identified in this study 
had at least one comorbid neuropsychiatric diagnosis, and 
approximately 25.1% of the total cohort had a record of 
two or more neuropsychiatric comorbid diagnoses. Psycho-
tropic medication was prescribed to 12.4% of individuals 
with ASD but without a record of comorbid neuropsychiatric 
conditions, which may suggest either the under-recording of 
the neuropsychiatric diagnoses or the use of psychotropic 
drugs to treat other issues.
Strengths and Limitations
Although the information provided by THIN database is gen-
eralisable to the UK population it only includes information for 
patients in primary care. Prescriptions produced by non-pri-
mary care settings, such as hospital discharge prescriptions and 
prescriptions provided by specialised centres, are not recorded 
in THIN. Prescriptions for some off-label drugs and controlled 
drugs may not be recorded either. This may lead to an underes-
timation of prescription rates. Furthermore, the database does 
not directly link prescriptions for drugs with their indication 
for use (whether this use is licensed or unlicensed). Because 
of this, it is not possible to determine whether recorded drugs 
were being prescribed to treat neuropsychiatric comorbidities 
of ASD. Last, information on patient compliance and adher-
ence to the prescribed medication cannot be obtained from the 
database; hence, we are not certain if the patients prescribed 
any of the drugs were taking them correctly, if at all.
Conclusions
Reported ASD prevalence has been increasing over time; in 
our study population, it reached 1.6 per 100 children in 2016. 
One-third of the identified cases with ASD were on psycho-
tropic medication. 12.4% of the treated cohort were prescribed 
antipsychotic drugs, of which 50.7% was risperidone and 
49.3% was other antipsychotic medication, the latter having 
been “off-label”. This suggests that the guidance on psycho-
tropic prescribing in children with ASD needs to be reviewed. 
We recommend further studies to obtain better data on the 
efficacy, tolerability and safety of psychotropic medication in 
patients with ASD, particularly children.
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